+ Translate

Candidemia in immunocompromised patients

, : Candidemia in immunocompromised patients. Clinical Infectious Diseases 14 Suppl 1: S120-S125

This study reviews data on patients with fungemia and confirms the high prevalence (50%) of infections caused by non-albicans species of Candida. Fungemia due to C. albicans or Torulopsis glabrata occurred significantly more often in patients with a solid tumor, while fungemia due to Candida tropicalis or Candida krusei was significantly more common in patients with hematologic malignancy (P = .001). For 31% of patients, only a single blood culture was positive for yeasts, and the prognosis for these patients was not significantly different than that for patients with three or more positive blood cultures (P = 1), including those who had C. albicans fungemia. The overall mortality rate was 41.8%, which is much lower than that previously reported in studies of patients with cancer. No significant difference was observed between patients treated with amphotericin B and those treated with fluconazole in this retrospective analysis. Although no significant difference was observed in the mortality rate among patients who had fungemia with or without neutropenia, the incidence of disseminated candidiasis was significantly higher among neutropenic patients (P = .03).

(PDF same-day service: $19.90)

Accession: 002042517

PMID: 1562683

DOI: 10.1093/clinids/14.supplement_1.s120

Submit PDF Full Text: Here

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Voss, A.; Hollis, R.J.; Wenzel, R.P.; Doebbeling, B.N., 1993: Investigation of the sequence of colonization and candidemia in non-immunocompromised patients. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33(0): 131

Noskin, G.A.; Pietrelli, L.; Coffey, G.; Gurwith, M.; Liang, L.J., 1998: Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. The efficacy and safety of amphotericin B colloidal dispersion (ABCD; Amphotec, Sequus Pharmaceuticals, Menlo Park, CA), a lipid complex of amphotericin B, were evaluated in immunocompromised patients with candidemia. These patients were recruited...

Dimopoulos, G.; Karabinis, A.; Samonis, G.; Falagas, M.E., 2007: Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. The purpose of this study was to compare the risk factors, clinical manifestations, and outcome of candidemia in immunocompromised (IC) and nonimmunocompromised (NIC) critically ill patients. Data were collected prospectively over a 2-year period...

Hennequin, C.; Girou, E.; Ferroni, A.; Brucker, G.; Blanche, S., 1996: Investigation of an outbreak of Candida parapsilosis candidemia in immunocompromised children. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 239

Bonvehi, P.; Lopardo, G.; Falco, A.; Temporiti, E.; Relloso, S.; Cassetti, L.; Ruttimann, R.; Herrera, F.; Smayevsky, J.; Stamboulian, D., 1996: Candidemia in adult HIV positive patients A report of five cases without risk factors for candidemia. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS Eleventh International Conference on AIDS, Vol Two One world: One hope : 94

Michalopoulos, A.S.; Geroulanos, S.; Mentzelopoulos, S.D., 2003: Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Study objectives: To develop and prospectively validate models of independent predictors of candidemia and candidemia-related death in cardiothoracic ICU (CICU) patients. Design: (1) An initial, prospective, one-center, case-control, independent p...

Kontoyiannis, D.P.; Reddy, B.T.; Hanna, H.; Bodey, G.P.; Tarrand, J.; Raad, I.I., 2002: Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. OBJECTIVES: To evaluate the risk factors associated with breakthrough candidemia in patients with cancer and to compare them with those of de novo candidemia in this patient population. DESIGN: Retrospective case series of 120 episodes of candidem...

Moreira D.O.iveira, M.S.; Mikami, Y.; Miyaji, M.; Imai, T.; Schreiber, A.Z.; Moretti Branchini, M., 2003: Prospective study for diagnosis of candidemia by PCR and blood cultures and variables associated with the development of candidemia in high risk patients. Background: The implementation for diagnosis of candidemia is important for the promptly initiation of antifungal therapy. Methods: Two hundred and twenty-nine patients with high risk for candidemia were prospectively followed-up during two years...

Rex, J.H.; Bennett, J.E.; Sugar, A.M.; Pappas, P.G.; van der Horst, C.M.; Edwards, J.E.; Washburn, R.G.; Scheld, W.M.; Karchmer, A.W.; Dine, A.P., 1994: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. Amphotericin B has long been the standard treatment for candidemia, but its use is complicated by its toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, has become available. W...

Phillips, P.; Shafran, S.; Garber, G.; Rotstein, C.; Smaill, F.; Fong, I.; Salit, I.; Miller, M.; Williams, K.; Conly, J.M.; Singer, J.; Ioannou, S., 1997: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. A randomized trial was conducted to compare the efficacy and safety of fluconazole versus that of amphotericin B in the treatment of candidemia in non-neutropenic adults. Enrollment was stratified by disease severity (APACHE II score). Patients we...